New drug duo aims to wipe out stomach cancer before surgery
NCT ID NCT07477444
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding two targeted drugs (zanidatamab and tislelizumab) to standard chemotherapy can completely eliminate HER2-positive gastroesophageal cancer before surgery. About 29 adults with operable, locally advanced disease will receive the combination before and after tumor removal. The main goals are safety and seeing if the cancer disappears entirely in the removed tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
- Can sequencing immunotherapy before chemo boost stomach cancer outcomes?
- Can a less extensive stomach surgery preserve appetite better?
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers
- New study aims to close gaps in cancer care for black patients
- Diet and exercise may boost quality of life for incurable cancer patients